CCR7 and Autoimmunity: In line with this, anti-CCR7 therapy in pre-clinical syngeneic mouse models of cancer, autoimmunity, GVHD, or inflammation did not uncover treatment-associated side effects (225, 273, 275) and CAP-100 toxicology studies in NHP did not reveal overt toxicities or autoimmune disease, all indicating superior tolerability of this novel therapy (244).